CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).
E. Gabriela Chiorean
Research Funding - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
Thomas J. Ervin
Research Funding - Celgene
Francis P. Arena
Research Funding - Celgene; Clinical Research Alliance
Jeffrey R. Infante
No relevant relationships to disclose
Venu Gopal Bathini
No relevant relationships to disclose
Tina Evans Wood
No relevant relationships to disclose
Paul N. Mainwaring
Consultant or Advisory Role - Novartis; Roche; Sanofi
Honoraria - Novartis; Roche; Sanofi
Robert T. Muldoon
No relevant relationships to disclose
Philip R. Clingan
No relevant relationships to disclose
Volker Kunzmann
Consultant or Advisory Role - Celgene
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene (U)
Honoraria - Abraxis BioScience
Research Funding - Celgene
Josep Tabernero
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; ImClone Systems; Lilly; Merck
Honoraria - Amgen; Merck; Novartis; Roche; Sanofi
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Amy Ko
Employment or Leadership Position - Celgene
Brian Lu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene